Sterile leuprorelin acetate depot microspheres for advanced prostate cancer are manufactured as aseptic polymer-encapsulated particles in which the nonapeptide is distributed within poly(D,L-lactide-co-glycolide) matrices. The terminal lyophilized cake contains approximately one part leuprorelin acetate to 8.8 parts PLGA by mass, with 3.75 mg, 7.5 mg, 22.5 mg, 30 mg, and 45 mg peptide strengths corresponding to 1, 3, 4, and 6-month dosing intervals. The production process uses a water-in-oil-in-water double emulsion followed by solvent extraction/evaporation, centrifugal or filtration-based harvesting, washing, and lyophilization with D-mannitol and gelatin as cryoprotectants and dispersants. In-process controls requiring release data include particle-size distribution by laser diffraction to USP <429>, assay and impurity profiles by HPLC to USP <621>, residual methylene chloride and ethyl acetate to USP <467>, sterility to USP <71>, bacterial endotoxins to USP <85>, and subvisible particulates to USP <787> in the reconstituted suspension. Compliance for the API and finished dosage form falls under ICH Q7, EU GMP Annex 1 for aseptic manufacturing, ISO 14644-1 Class 5 cleanroom classification, and 21 CFR 210.1/211.165 for current good manufacturing practice and release testing. Terminal product types include single-dose vials and prefilled dual-chamber syringes for intramuscular injection after reconstitution with the supplied diluent. Terminal sterilization of the polymer-peptide powder is generally avoided because heat, gamma irradiation, or ethylene oxide can increase degradation products and alter drug-release kinetics, so aseptic processing remains the controlling manufacturing route. The reconstituted suspension must be administered immediately after complete wetting; settling of microspheres occurs, and improper needle gauge selection below 20 to 22 gauge can obstruct flow.

What Limits Peptide Loading in PLGA Depot Microspheres for Estrogen-Dependent Gynecological Indications?

For endometriosis and uterine fibroids, depot products are released as 3.75 mg one-month and 11.25 mg three-month presentations, requiring the same aseptic microsphere platform but with adjusted total PLGA mass and dose-proportional peptide loading. Peptide addition ratio remains close to the prostate cancer depot design, with PLGA-to-peptide mass ratio near 8.8:1, and the higher 11.25 mg payload increases polymer content proportionally to sustain release across 12 weeks. Production differences are mainly in fill weight, reconstitution volume, and release acceptance windows, not in the primary emulsion unit operation; the scale-up parameters that most affect batch-to-batch variance are primary emulsion droplet size, solvent removal rate, and inner aqueous phase osmotic pressure. Compliance includes 21 CFR 211.165 release testing, ICH Q7 API GMP, USP <905> uniformity of dosage units, USP <711> Apparatus 4 in vitro release testing, and the same sterility/endotoxin/particulate panel described for all injectable depots. Downstream terminal products are single-dose vials or dual-chamber syringes with a sterile diluent containing carboxymethylcellulose sodium, D-mannitol, and polysorbate 80, administered by intramuscular injection after reconstitution. In public regulatory labels, the precise PLGA lactide-to-glycolide ratio, molecular weight distribution, and end-group chemistry are not disclosed; the controlling variable set is therefore defined by the manufacturer’s design space and performance qualification, not by universal product-specific numbers. For gynecological indications, repeated monthly or quarterly injection is required because ovarian estradiol suppression is reversible after drug washout, and low-level follicle-stimulating hormone escape may occur if the depot is under-dosed or incorrectly reconstituted.

Pediatric central precocious puberty introduces weight-banded dosing to depot manufacturing and fill control, with 7.5 mg assigned to children ≤25 kg, 11.25 mg for >25 kg to 37.5 kg, and 15 mg for >37.5 kg body weight according to approved one-month depot labeling. The addition ratio is held constant across the three strengths, but lower total peptide mass makes fill-weight accuracy and reconstitution losses proportionally more critical; release testing therefore adds USP <905> content uniformity and tighter in-house fill-weight controls than adult high-dose depots. The production process remains aseptic double-emulsion microsphere manufacturing followed by lyophilization, except that batch sizes may be smaller and homogenization speed is re-validated to avoid excessive shear that fragments the peptide-loaded polymer phase. Terminal product types are single-dose vials or prefilled dual-chamber syringes for intramuscular injection. Compliance for the pediatric injectable includes 21 CFR 211.165, ICH Q7, EU GMP Annex 1, USP <71>, USP <85>, USP <790> visible particulate inspection, and the applicable leuprorelin acetate monograph. The product should not be mixed with other injectable products or diluents, and the suspension should not be vigorously shaken because air entrapment can break microspheres or create foam that alters withdrawal volume. Long-term pediatric treatment requires monitoring of growth velocity and bone age, but those clinical parameters are outside API manufacturing quality and remain in the approved labeling.

Aqueous Subcutaneous Injection Formulation and Ovarian Suppression Protocols

The aqueous subcutaneous solution is a daily or microdose injectable, not a depot, and is manufactured as a sterile filtered peptide solution. The standard reference composition is leuprorelin acetate 5 mg/mL, most commonly supplied as 1 mg/0.2 mL single-dose vials or 5 mg/mL multi-dose vials containing 9 mg/mL benzyl alcohol as antimicrobial preservative, sodium chloride for isotonicity, and water for injection; pH is adjusted to a compendial range using dilute acetic acid or sodium hydroxide. Production uses dissolution of the API in cooled water for injection, pH adjustment, terminal sterile filtration through a 0.22 µm polyethersulfone membrane, and aseptic filling under ISO 14644-1 Class 5 conditions. Release testing includes sterility to USP <71>, bacterial endotoxins to USP <85>, assay and degradation products to USP <621>, particulate matter to USP <787>, and preservative content where applicable. In assisted reproduction, microdose leuprorelin acetate protocols commonly use 40 µg subcutaneously twice daily for pituitary suppression before or during gonadotropin stimulation; the 1 mg/0.2 mL presentation requires precise syringe withdrawal and is therefore paired with low dead-space insulin-type syringes in clinical practice. Terminal product types include multi-dose vials for short-term multi-day use and single-dose vials or prefilled syringes to reduce preservative exposure and handling error. The aqueous formulation is not interchangeable with PLGA depot products because the terminal half-life is shorter and the hypothalamic-pituitary-ovarian effect is reversed rapidly after discontinuation. Multi-dose vial handling is restricted by compendial antimicrobial effectiveness and repeated-puncture in-use dating; aseptic technique and storage conditions must follow label requirements.

When N-Methyl-2-Pyrrolidone and PLGA Form an In Situ Solid Depot

An alternative non-microsphere injectable configuration uses in situ precipitation: lyophilized leuprorelin acetate is packaged in a syringe separate from a non-aqueous PLGA solution in N-methyl-2-pyrrolidone. Immediately before subcutaneous injection, the syringes are connected and the contents are cycled between syringes until a homogeneous suspension or solution is formed; after injection, N-methyl-2-pyrrolidone exchanges into tissue fluid, and the polymer precipitates to form a solid, biodegradable depot. Kit strengths are 7.5 mg, 22.5 mg, 30 mg, and 45 mg, corresponding to 1, 3, 4, and 6-month dosing intervals. The precise PLGA-to-solvent ratio is product-defined and validated by in vitro precipitation rate, viscosity at injection, and in vivo release profile; the peptide addition ratio is fixed by the drug syringe, while the vehicle syringe weight is selected to form the depot matrix. Production requires the drug syringe to be filled aseptically with micronized or lyophilized API, and the vehicle syringe to be prepared as a sterile non-aqueous polymer solution; compatibility of the polymer solution with elastomer closures and luer connectors is a critical packaging parameter because N-methyl-2-pyrrolidone is an aggressive solvent for some plastics and elastomers. Compliance includes 21 CFR 210.1/211.165, ICH Q7, ICH Q3C residual solvent limits for N-methyl-2-pyrrolidone, ISO 10993-1 biocompatibility evaluation, USP <71>, USP <85>, and USP <788> particulate matter for injections. Terminal product types are single-use, two-syringe mixing kits with luer connectors and injection needles, generally for subcutaneous administration. Aqueous diluents must not be added to the vehicle, because premature polymer precipitation can create non-injectable gels or needle blockage; mixing should be performed immediately before injection because the viscosity increases as solvent diffusion begins, and the depot must be placed subcutaneously, not intramuscularly or intradermally, to achieve the intended release profile.

Oral tablet, capsule, and granule routes for leuprorelin acetate remain development-stage rather than commercial pharmacopoeial products because the nonapeptide undergoes gastric acid hydrolysis and brush-border peptidase cleavage before absorption, yielding negligible unmodified oral bioavailability. Investigational solid oral systems under feasibility testing use enteric-coated capsules or granules, lipid-based dispersions, or transient permeation enhancers such as medium-chain fatty acid salts; published development formulations generally cite peptide loadings below 10% w/w, but commercial quantitative compositions and human pharmacokinetic data for this specific configuration are limited. The downstream production methods under evaluation include low-humidity wet granulation, spray-drying of peptide-lipid dispersions onto porous carriers, and direct compression or capsule filling with tight environmental control below 30% relative humidity because peptide aggregation and oxidative degradation are accelerated by moisture and heat. Compliance for investigational supplies is governed by 21 CFR 312, ICH M3(R2) nonclinical safety guidance, ICH Q7 for API GMP, and current GMP for investigational medicinal products; in vitro quality follows USP <711> dissolution testing at pH 1.2 and 6.8, USP <905> uniformity of dosage units, and USP <621> assay and related substances. Terminal investigational product types include hard-shell capsules, immediate-release or enteric-coated tablets, and granule-filled sachets. Because no oral leuprorelin acetate monograph exists as of 2026 and approved labeling for parenteral depot products does not support oral substitution, oral formulations cannot be considered interchangeable with injectable controlled-release depots without dedicated bioequivalence and efficacy data.